IGC - Latest News
IGC Pharma, Inc. (IGC), operates in Healthcare / Biotechnology, trades on AMEX.
Market capitalization stands near $26.3M. Beta to the broader market is 0.45.
The article list below shows the most recent IGC headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IGC Headlines
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
accessnewswire.com - Jun 23, 2026
Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahe
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
accessnewswire.com - Jun 11, 2026
Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Explo
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
accessnewswire.com - Jun 9, 2026
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
accessnewswire.com - Jun 2, 2026
Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC,
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
accessnewswire.com - May 19, 2026
- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "C
How News Affects IGC Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IGC's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IGC news questions
- What is the latest IGC news headline?
- The most recent IGC headline (Jun 23, 2026) is "IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IGC news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IGC news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IGC options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.